<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02474121</url>
  </required_header>
  <id_info>
    <org_study_id>BB-IDE 13996 (CA)</org_study_id>
    <nct_id>NCT02474121</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Autologous Concentrated Bone Marrow Aspirate for Critical Limb Ischemia - Continued Access</brief_title>
  <acronym>MOBILE-CA</acronym>
  <official_title>MarrOwStim™ PAD Kit for the Treatment of Critical LimB IschemIa (CLI) in Subjects With Severe Peripheral ArteriaL DiseasE (PAD) (MOBILE) - Continued Access</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zimmer Biomet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zimmer Biomet</source>
  <brief_summary>
    <textblock>
      This study will continue to evaluate the performance of the MarrowStim™ PAD Kit to treat&#xD;
      subjects with critical limb ischemia (CLI) caused by severe PAD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a continued access enrollment intended for subjects with critical limb ischemia (CLI)&#xD;
      that are unsuitable for revascularization. The investigational treatment utilizes autologous&#xD;
      concentrated bone marrow aspirate (cBMA) at the point of care. The bone marrow aspirate is&#xD;
      obtained from the subject's hip, concentrated with a bone marrow concentration device, and&#xD;
      delivered intramuscularly to the affected limb. Subjects meeting the inclusion/exclusion&#xD;
      criteria will be treated with the MarrowStim™ PAD Kit and followed for a total of five years.&#xD;
      Information on subject outcomes, such as the occurrence of amputation and death, as well as&#xD;
      measurements of rest pain, blood flow (ankle-brachial index, toe-brachial index), and quality&#xD;
      of life will be collected. Safety information (via adverse event reporting) will also be&#xD;
      collected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>Peripheral Arterial Disease</condition>
  <condition>Peripheral Vascular Diseases</condition>
  <condition>Critical Limb Ischemia</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bone marrow concentration device</intervention_name>
    <description>Collection of autologous bone marrow aspirate and point-of-care concentration using the bone marrow concentration device, followed by intramuscular injection of concentrated bone marrow aspirate (cBMA) into the affected limb</description>
    <other_name>MarrowStim™ PAD Kit</other_name>
    <other_name>Bone Marrow Concentrate</other_name>
    <other_name>Bone Marrow Mononuclear Cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Unilateral or bilateral lower extremity ischemia due to advanced peripheral arterial&#xD;
             disease&#xD;
&#xD;
          -  Unsuitable for revascularization&#xD;
&#xD;
          -  Minor tissue loss (Rutherford Category 5) or ischemic rest pain (Rutherford Category&#xD;
             4)&#xD;
&#xD;
          -  Competent to give consent&#xD;
&#xD;
          -  No current malignancy or history of previous malignancy within the last five years,&#xD;
             with the exception of adequately treated non-melanoma skin cancer (evidence of&#xD;
             standard preventative cancer screenings required)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major tissue loss (Rutherford Category 6)&#xD;
&#xD;
          -  Diabetics with uncontrolled or untreated proliferative retinopathy&#xD;
&#xD;
          -  Poorly controlled diabetes mellitus with HbA1C &gt; 10%&#xD;
&#xD;
          -  Uncompensated congestive heart failure and/or other conditions that preclude general&#xD;
             anesthesia&#xD;
&#xD;
          -  Myocardial infarction or stroke within last 90 days&#xD;
&#xD;
          -  Elevated liver function tests (AST or ALT more than twice the upper limit of normal)&#xD;
&#xD;
          -  Renal disease (creatinine &gt; 2.5 mg/dl) or chronic hemodialysis&#xD;
&#xD;
          -  White blood cell count &lt; 3,000/µL or &gt; 15,000/µL, platelet count &lt; 100,000/µL, or&#xD;
             hematocrit &lt; 32%&#xD;
&#xD;
          -  Topical growth hormone therapy within last 90 days, or injected growth hormone therapy&#xD;
             within last 180 days&#xD;
&#xD;
          -  Disease of central nervous system and/or other conditions that impair cognitive&#xD;
             function&#xD;
&#xD;
          -  Two or more episodes of pulmonary embolus with a documented DVT in index leg or&#xD;
             history of DVT in index leg without evidence of clot resolution&#xD;
&#xD;
          -  Current infection of index leg&#xD;
&#xD;
          -  Pregnant women (negative urine pregnancy test required)&#xD;
&#xD;
          -  Lower extremity venous disease with pitting edema in index leg&#xD;
&#xD;
          -  Recent history (in the 6 months prior to screening) of bone marrow disease or&#xD;
             treatment with any medication or procedure which adversely affects the bone marrow and&#xD;
             would prohibit transplantation&#xD;
&#xD;
          -  Current osteomyelitis in index leg&#xD;
&#xD;
          -  Existing HIV diagnosis&#xD;
&#xD;
          -  Organ transplant recipients&#xD;
&#xD;
          -  Known terminal disease process with life expectancy less than one year&#xD;
&#xD;
          -  Severe concomitant disease(s) or any additional condition(s) which the investigator&#xD;
             feels constitute(s) criteria for exclusion of a particular subject&#xD;
&#xD;
          -  Major amputation required within 30 days&#xD;
&#xD;
          -  Inclusion in any other clinical study that may affect the outcome of this study&#xD;
&#xD;
          -  Uncorrected stenosis(es) of greater than 50% in the common and/or external iliac&#xD;
             artery and/or common femoral artery of the index leg.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Central Arkansas Veterans Healthcare System</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Name Medical Center</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College/New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Pittsburgh Healthcare System</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Murphy MP, Lawson JH, Rapp BM, Dalsing MC, Klein J, Wilson MG, Hutchins GD, March KL. Autologous bone marrow mononuclear cell therapy is safe and promotes amputation-free survival in patients with critical limb ischemia. J Vasc Surg. 2011 Jun;53(6):1565-74.e1. doi: 10.1016/j.jvs.2011.01.074. Epub 2011 Apr 22.</citation>
    <PMID>21514773</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 15, 2015</study_first_submitted>
  <study_first_submitted_qc>June 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2015</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

